Andrew Wilson is a Respiratory physician. ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Albany Street
Shapiro 9, Suite B
Boston, MA 021182526
Telephone
617-638-7480Registry record last updated 11 Jul 2014.
Clinical trials
- Poly-unsaturated Fats for Improving Nasal Polyps and Asthma
Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust
- Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole
Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust
- Asthma Breath Biomarker Assessment
Sponsor: University of East Anglia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
- Medtronic, Inc.Program year20242 payments
- PFIZER INC.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
100%Human alpha-1 Proteinase Inhibitor100%Prolastin C57%Zemaira16%Aralast Np14%Glassia13%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:
- Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells
Boston University Medical Campus
FY2026$758,098R01HL166407 - Elucidating the contribution of lung epithelial gain of function toxicity to AATD disease pathogenesis
Boston University Medical Campus
FY2026$464,118P01HL170952
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”